Clinical trials: Nonsmall Cell Lung Cancer
Nonsmall Cell Lung Cancer Stage III
Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy
This is a multicenter, phase 2 non-randomized study to investigate the clinical feasibility and therapeutic efficacy of employing a MDT-based strategy in unresectable stage III ALK positive NSCLC following neoadjuvant alectinib…
- Trial name
- NCT07573696
- Testing
- After neoadjuvant alpelisib combined with chemotherapy, a multidisciplinary decision was made
- Volunteers
- 50 people
- Sponsor
- Wen-zhao ZHONG
Lung Cancer, Nonsmall Cell
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
This study aims to incorporate circulating tumor DNA (ctDNA)-minimal residual disease (MRD) to personalize the administration of consolidation toripalimab therapy in resected stage IB-IIIA non-small-cell lung cancer (NSCLC) after…
- Trial name
- CONTINUE (NCT06426511)
- Testing
- Toripalimab+Chemotherapy, Toripalimab+Chemotherapy followed by consolidation toripalimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Lung Cancer, Nonsmall Cell
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune…
- Trial name
- NCT05415358
- Testing
- Blood and tissue samples
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Wake Forest University Health Sciences
Nonsquamous Nonsmall Cell Neoplasm of Lung
Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy
Maitake is reported with immunomodulatory functions against tumor growth in terms of its unique molecular structure, β-glucan polysaccharides within 1, 6 main chain having 1, 3 branches and a 1, 3 main chain having 1, 6 branches…
- Trial name
- NCT05764928
- Testing
- BLEX 404
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Rgene Corporation
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
The main purpose of this study is to see if the combination of nivolumab, ipilimumab and nintedanib is effective in people with non- small cell lung cancer.
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell, Non Small Cell Lung Cancer Metastatic
- Trial name
- NCT03377023
- Testing
- Nivolumab, Ipilimumab, Nintedanib
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) with concurrent chemotherapy in the management of stage II and III non-small cell lung cancer (NSCLC).
- Conditions
- Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- NCT05873439
- Testing
- Genomically Guided Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Nonsmall Cell Lung Cancer, NSCLC
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following…
- Trial name
- NCT02973789
- Testing
- NovoTTF-200T, Immune checkpoint inhibitors or docetaxel
- Where
- 124 sites in United States, Austria and 16 more
- Volunteers
- 291 people
- Sponsor
- NovoCure GmbH
Lung Cancer, Nonsmall Cell, Lung Cancer
Palliative Thoracic ImmunoRT
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada.
- Trial name
- NCT03705806
- Testing
- Radiation combined with immunotherapy
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Metastatic Nonsmall Cell Lung Cancer
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
This is a Phase I study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).
- Trial name
- NCT06228482
- Testing
- [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, Davis
Lung Cancer, Nonsmall Cell
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
- Trial name
- NCT04691817
- Testing
- Atezolizumab, Tocilizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties.
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
- Trial name
- NCT05860296
- Testing
- SLC-391, pembrolizumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- SignalChem Lifesciences Corporation
Stage IV Non-small Cell Lung Cancer, Targeted Therapy
Patient-centered, Optimal Integration of Survivorship and Palliative Care
The goal of this study is to develop and test the feasibility of a supportive care model (POISE) for patients with metastatic Non-small Cell Lung Cancer (NSCLC).
- Conditions
- Stage IV Non-small Cell Lung Cancer, Targeted Therapy, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT04900935
- Testing
- POISE
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Massachusetts General Hospital
Cancer, Tumor, Solid
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or…
- Conditions
- Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05082610
- Testing
- HMBD-002, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hummingbird Bioscience
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Lung Cancer, Lung Cancer Metastatic
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage IIIB
- Trial name
- NCT06555263
- Testing
- Luveltamab tazevibulin
- Where
- 7 sites in United States
- Sponsor
- Sutro Biopharma, Inc.
Nonsmall Cell Lung Cancer, Brain Metastases
X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive NSCLC patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures.
- Trial name
- NCT03753685
- Testing
- X-396(Ensartinib) Capsule
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Fudan University
Lung Cancer, Nonsmall Cell
[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
In this pilot study, healthy volunteers and patients with Non-Small Cell Lung Cancer will undergo [18F]F-AraG dynamic imaging on the uEXPLORER total body Positron Emission Tomography/Computerized Tomography scanner to obtain…
- Trial name
- NCT04678440
- Testing
- [18F]F-AraG Imaging
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
There has been limited benefit with angiogenesis inhibitor drugs in molecularly unselected patients in non-small cell lung cancer (NSCLC).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
- Trial name
- NCT02299141
- Testing
- Nintedanib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Lung Cancer, Nonsmall Cell, Lung Cancer
Trial of NanoPac Intratumoral Injection in Lung Cancer
This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
- Trial name
- NCT04314895
- Testing
- NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- NanOlogy, LLC